Annapolis-based Alphyn Biologics, a clinical-stage dermatology company developing multi-target therapeutics, announced Thursday it has closed a Series A financing round of approximately $3.3 million.

The MarketWatch News Department was not involved in the creation of this content. Financing funds the global Phase 2b clinical trial in atopic dermatitis and Phase 2 clinical program in molluscum ...

When startup Alphyn Industries speaks of jacketing an Apple iPad, the company means it in a literal sense-- this PADX-1 Ledge is a form-fitting polyester and silicone pullover with a zippered shelf to ...

ANNAPOLIS, Md., Oct. 27, 2025 /PRNewswire/ -- Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics ®, announced today that the U.S. Patent and Trademark ...

Patent covers compositions and methods of use of drug formulation for Zabalafin Hydrogel ANNAPOLIS, Md., Dec. 10, 2024 /PRNewswire/ -- Alphyn, a clinical-stage dermatology company developing ...

ANNAPOLIS, Md., Jan. 10, 2025 /PRNewswire/ -- Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that CEO Neal Koller will present at ...

First topical therapeutic to directly treat the immuno-inflammatory and bacterial causes of the disease at all stages, from AD onset through infection Alphyn Biologics is a clinical-stage dermatology ...

As an Amazon Associate, we earn from qualifying purchases. TweakTown may also earn commissions from Newegg and other affiliate partners at no extra cost to you. PowerColor's first wireless gaming ...

WANdisco's shares have been suspended due to an accounting scandal and misrepresentation of revenues. The company's technology has been validated by groups like Microsoft and GoDaddy, and has ...

ANNAPOLIS, Md., Dec. 12, 2025 /PRNewswire/ -- Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics ®, today announced the close of its $25 ...